What did @kmart_fit actually say?
The claim is blunt: if your testicles are shrinking on testosterone replacement therapy, your doctor "has no clue" what they're doing. The fix, according to this creator, is simple, just add enclomiphene or HCG at a low dose and the problem goes away. The implication is that testicular atrophy on TRT is always a sign of medical negligence, not a predictable physiological response.
To be fair, the creator is pointing at a real phenomenon. Testicular atrophy does happen on TRT, and there are legitimate clinical tools to address it. But the framing, that it "should not be happening" and that any doctor who doesn't prevent it is clueless, is an overreach that flattens a genuinely nuanced clinical conversation.
Does the science back this up?
Partly, but not the way it's presented. Testicular atrophy during exogenous testosterone therapy is well-documented and expected. It is not a mistake. It is a direct consequence of the hypothalamic-pituitary-gonadal (HPG) axis suppression that TRT causes by design.
When you introduce exogenous testosterone, the hypothalamus reduces gonadotropin-releasing hormone (GnRH), which suppresses LH and FSH from the pituitary. Without LH stimulation, the Leydig cells in the testes stop producing testosterone. Without FSH, Sertoli cells reduce spermatogenesis. The testes, deprived of their normal hormonal signals, physically reduce in volume. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) documented this suppression comprehensively in men on testosterone therapy.
HCG, which mimics LH, can preserve testicular volume and intratesticular testosterone by keeping Leydig cells active during TRT. Paduch et al. (2005, Journal of Urology) and later Hsieh et al. (2013, Journal of Urology) showed HCG co-administration maintained testicular volume and sperm parameters in men on exogenous testosterone. Enclomiphene, a selective estrogen receptor modulator, stimulates endogenous LH and FSH and is used in some protocols, though it has a different mechanism and evidence base compared to HCG.
What did they get wrong (or right)?
They got the mechanism directionally right: TRT suppresses natural production, and adjunct therapies like HCG can counteract atrophy. That's real. But the assertion that shrinkage "should not be happening" is factually wrong as a blanket statement. Testicular atrophy is a predictable, well-understood side effect of HPG axis suppression. It is not inherently dangerous for men who are not concerned with fertility preservation, and many clinical guidelines do not mandate HCG co-administration for all TRT patients.
The American Urological Association's 2018 guidelines on testosterone deficiency do not require HCG as a standard component of TRT protocols. HCG and enclomiphene are appropriate adjuncts for men who want to preserve fertility or testicular volume, but calling their absence medical negligence is simply not supported by the evidence or by established clinical standards.
The creator also conflates two different drugs, HCG and enclomiphene, as interchangeable solutions without acknowledging their distinct mechanisms, evidence profiles, and appropriate use cases. That's a meaningful omission for an audience that may act on this advice.
What should you actually know?
Testicular atrophy on TRT is expected, not a red flag on its own. What matters is your clinical goals. If fertility preservation matters to you, or if testicular volume loss is personally distressing, that's a real and valid conversation to have with a prescribing clinician. HCG co-therapy has solid evidence for maintaining intratesticular testosterone and sperm parameters. Hsieh et al. (2013, Journal of Urology) found that low-dose HCG (500 IU every other day) maintained intratesticular testosterone in men on exogenous testosterone without disrupting serum testosterone levels.
Enclomiphene works differently. It blocks estrogen receptors in the hypothalamus and pituitary, which increases GnRH, LH, and FSH. It is not the same as HCG, and the two are not simply interchangeable. Neither should be added to a protocol without clinical evaluation.
The bottom line: atrophy without adjunct therapy is not negligence. Atrophy without a conversation about your goals might be worth discussing with your provider. Those are different things.
Who should actually be concerned?
Men on TRT who want to father children should absolutely discuss fertility-preserving options with their doctor before starting therapy. Suppression of spermatogenesis is a real and sometimes prolonged consequence of exogenous testosterone, and it is not always reversible quickly after stopping. Jarow et al. (1989, Fertility and Sterility) documented recovery of sperm production after testosterone therapy, but recovery timelines vary widely.
Men who are not concerned about fertility and are not bothered by mild volume changes do not necessarily need HCG or enclomiphene. That's a clinical decision, not a YouTube shortcut. If your provider has not discussed your fertility goals before starting TRT, that is a legitimate gap worth raising, but it is a different claim than the one this video makes.